Dr. Nicholas Manguso, MD

Dr. Manguso practices at Renown Regional Medical Center in Reno, Nevada, part of Renown Health.

Dr. Manguso's NPI, 1093199457, was assigned on July 16, 2015. Dr. Manguso graduated from Albert Einstein College of Medicine in 2013. Dr. Manguso's Nevada license number on file is 22231.

Dr. Manguso's primary practice is Renown Regional Medical Center, at 1155 Mill Street, Reno, NV 89502 in Washoe County. The practice phone is (775) 982-4100.

Dr. Manguso's primary practice is Renown Regional Medical Center in Reno, Nevada, part of Renown Health. Dr. Manguso is also affiliated with Renown South Meadows Medical Center. The medical group on file is Renown Health. Dmand AI also links Dr. Manguso to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manguso practices, 5 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Manguso's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Manguso is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Manguso's licenses on file in 3 states: Nevada, Florida and California.

Dmand AI lists abdominal adhesion surgery, colon removal, esophagus, stomach, or upper small intestine surgery, gallbladder removal and removal of damaged skin or skin graft among the conditions Dr. Manguso treats.

CMS data shows 218 Medicare services from Dr. Manguso across 7 procedure codes in 2024, for 138 Medicare patients. Medicare paid $20,727 for them.

CMS counts 138 Medicare patients who saw Dr. Manguso in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.44, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Manguso's median patient age at 71, with 49% women.

In 2024, Dr. Manguso wrote 61 Medicare Part D claims for 28 patients. 84% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $40 in total drug cost. In 2021, CMS named 27 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Manguso for performance year 2024, reported as part of a group. Dr. Manguso accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manguso as offering telehealth. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. Manguso, more than 64% of the clinicians it reports for that procedure.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 16 papers to Dr. Manguso, published from 2018 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Neoadjuvant Therapy, Venous Thromboembolism and Breast Neoplasms. Dr. Manguso has published most often in Ann Surg Oncol. Dr. Manguso's most frequent co-authors are Alexandra Gangi, MD, Armando E. Giuliano, FACS, MD and Jun Gong.

CMS Open Payments shows 13 general payments to Dr. Manguso from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Histosonics, Inc. paid the most, $8,446.

Dr. Manguso graduated from Albert Einstein College of Medicine in 2013.

Dr. Manguso is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.